The global hyperpigmentation treatment market, valued at $1.52 billion in 2025, is projected to grow to $2.85 billion by 2035 at a CAGR of 6.5%. Growth is fueled by rising consumer awareness of skin aesthetics, increasing cases of pigmentation disorders like melasma and post-inflammatory hyperpigmentation, and demand for advanced treatments such as laser therapy, chemical peels, and microneedling. North America leads the market, with the U.S. expected to reach $0.93 billion by 2035. Asia-Pacific is the fastest-growing region due to rising incomes and beauty consciousness. Key players include AbbVie, L'Oréal, and Johnson & Johnson.
The Health Care Select Sector SPDR ETF (XLV) is down about 3% year-to-date despite a 14% gain over the past year. The fund's performance hinges on drug pricing policies and key product pricing, especially from Eli Lilly, which dominates XLV with its ...
AbbVie is close to acquiring Apogee Therapeutics for $10.9 billion in cash. Apogee is developing a long-acting drug for atopic dermatitis that blocks the IL-13 protein causing eczema. The drug is expected to enter Phase 3 trials later this year, pote...
The Schwab U.S. Dividend Equity ETF (SCHD) provides investors with a low-cost, diversified portfolio of U.S. companies known for consistent dividend growth, making it an attractive option for those seeking a stable and growing income stream in retire...
AbbVie recently received FDA approvals for Decnupaz and Skinvive by Juvederm, enhancing its product portfolio. The company also reported positive Phase 3 trial results for chronic lymphocytic leukemia treatment, supporting future oncology growth. Add...
AbbVie announced a quarterly cash dividend of $1.73 per share, payable on August 14, 2026, to shareholders of record as of July 15, 2026. Since its founding in 2013, AbbVie has increased its dividend by over 330%, reflecting its strong commitment to ...
